ara-C


Also found in: Acronyms.

cytarabine

 [si-tar´ah-bēn]
an antimetaboliteantineoplastic agent that inhibits DNA polymerase and thus inhibits DNA synthesis during a specific phase of the cell cycle. Administered intravenously to treat acute myelogenous and other types of leukemia. It is also injected intrathecally to treat meningitis associated with leukemia or lymphoma. Called also cytosine arabinoside.

ara-C

Cytarabine, see there.
References in periodicals archive ?
The absorption peak at 809 [cm.sup.-1] assigned to Ara-C was found in ABMs-GP.
The release of Ara-C from BMs-based conjugates was assayed by suspending them in PBS (pH 7.4) to mimic pH of blood plasma [32].
In summary, Ara-C was immobilized on BMs efficiently by using GP, G, and direct absorption.
Caption: SCHEME 1: Graphical illustration showing the Ara-C immobilization on BMs through various methods and their resultant end products, (a) genipin (GP) cross-linker (ABMs-GP), (b) glutaraldehyde (G) cross-linker (ABMs-G), and (c) direct absorption method (ABMs).
Caption: FIGURE 2: The FTIR spectra of (a) Ara-C, (b) ABMs-GP, (c) ABMs-G, (d) ABMs, and (e) BMs.
Cell lines, peripheral blood, and bone marrow blasts were treated with 25 [micro]mol/L Ara-C for 30 min at 37 [degrees]C and 5% C[O.sub.2].
Ara-C toxicity was also assayed with a 3-day cytotoxicity assay using the Cell Titer-Glo[R] Luminescent Cell Viability Assay kit (Promega, www.promega.
(15), expressing the human dCK gene, exhibited reduced relative growth in the presence of Ara-C in minimal medium but not in a rich growth medium, due to incorporation of cytosine triphosphate instead of the toxic analog Ara-CTP into bacterial DNA.
To measure Ara-C response in a nutrient-rich intracellular environment, an alternative cdd-deficient mutant of a bioluminescent E.
2, A and B) is similar to that observed with Ara-C (Fig.
AML cell lines and leukemic cell samples from AML patients with known clinical outcome to Ara-C treatment were used to evaluate the assay outlined by the schematic in Fig.
The 3-day cytotoxicity test also showed that cells from patient sample CR were significantly more sensitive to Ara-C compared with cells from patient sample NR (Fig.